AtaiBeckley (ATAI) drew fresh attention after releasing second quarter 2026 results, reporting revenue of US$1.7 million and a net loss of US$32.52 million, while loss per share from continuing operations improved year over year.

AtaiBeckley’s recent earnings release comes after a sharp shift in sentiment, with a 90 day share price return of 78.24% and a 3 year total shareholder return above 300%, although the 5 year total shareholder return remains negative.

If this kind of move has your attention, it might be a good moment to widen your watchlist with a curated set of resilient companies by checking out the 79 resilient stocks with low risk scores

AtaiBeckley’s pipeline and recent share price surge point to a company that many investors now view as stronger than the last few years suggested. The next step is to assess whether that story is already fully reflected in the valuation.

Preferred Price-to-Book Multiple of 15.3x: Is It Justified For AtaiBeckley?

AtaiBeckley shares last closed at $7.29, and the stock is described as expensive on a price-to-book basis compared with both its industry and direct peers. That immediately puts the current valuation under a spotlight for anyone trying to separate momentum from fundamentals.

The price-to-book multiple compares the market value of a company to the accounting value of its net assets. For a clinical stage biopharma stock like AtaiBeckley, this often reflects what investors are willing to pay for an early stage pipeline and future revenue potential rather than current earnings or cash flows.

In this case, AtaiBeckley trades on a P/B of 15.3x, while the broader US Pharmaceuticals industry averages 2.6x and a closer peer set averages 8.1x. That is a very wide gap. It suggests the market is attaching a much higher value to AtaiBeckley’s assets and development programs than to those of the typical pharma stock and even above similar peers.

Because there is no fair ratio estimate available, there is no quantitative reference point for where that P/B multiple could settle if sentiment or expectations shift. The only anchor here is the clear premium to both industry and peer benchmarks.

Result: Price-to-book of 15.3x (OVERVALUED).

However, AtaiBeckley still relies on unproven clinical assets and ongoing net losses, so any trial setbacks or funding pressures could quickly challenge the current optimism.

Next Steps

The mix of strong recent returns and a rich P/B multiple shows how split opinion on AtaiBeckley has become. Act quickly and review both sides of the story by checking the 1 key reward and 4 important warning signs

Looking For More Investment Ideas Beyond AtaiBeckley?

If AtaiBeckley has sharpened your focus on opportunities, now is a good time to widen your search and stress test your portfolio with fresh ideas.

• Target potential value opportunities and compare them against AtaiBeckley using the 50 high quality undervalued stocks.
• Strengthen your income stream with stocks that prioritise reliable payouts by checking the 11 dividend fortresses.
• Spot earlier stage opportunities with solid fundamentals before they reach a wider audience using the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.